MX369039B - Vacuna contra el circovirus porcino tipo 2. - Google Patents

Vacuna contra el circovirus porcino tipo 2.

Info

Publication number
MX369039B
MX369039B MX2016007224A MX2016007224A MX369039B MX 369039 B MX369039 B MX 369039B MX 2016007224 A MX2016007224 A MX 2016007224A MX 2016007224 A MX2016007224 A MX 2016007224A MX 369039 B MX369039 B MX 369039B
Authority
MX
Mexico
Prior art keywords
virus type
circo virus
porcine circo
vaccine against
against porcine
Prior art date
Application number
MX2016007224A
Other languages
English (en)
Other versions
MX2016007224A (es
Inventor
Vicky Fachinger
Melanie Sno
Hendrik Witvliet Maarten
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49680926&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX369039(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of MX2016007224A publication Critical patent/MX2016007224A/es
Publication of MX369039B publication Critical patent/MX369039B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una vacuna que comprende un inmunógeno que no se replica del circovirus porcino tipo 2 para usarse en el tratamiento profiláctico de un animal que tiene anticuerpos circulantes dirigidos contra el circovirus porcino tipo 2 contra una infección por el circovirus porcino tipo 2 patogénico por una sola dosis de administración de la vacuna en la dermis del animal.
MX2016007224A 2013-12-03 2014-12-02 Vacuna contra el circovirus porcino tipo 2. MX369039B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13195515 2013-12-03
PCT/EP2014/076224 WO2015082458A1 (en) 2013-12-03 2014-12-02 Vaccine against porcine circo virus type 2

Publications (2)

Publication Number Publication Date
MX2016007224A MX2016007224A (es) 2016-07-21
MX369039B true MX369039B (es) 2019-10-25

Family

ID=49680926

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016007224A MX369039B (es) 2013-12-03 2014-12-02 Vacuna contra el circovirus porcino tipo 2.

Country Status (13)

Country Link
US (1) US10130698B2 (es)
EP (1) EP3076996B1 (es)
JP (1) JP6605469B2 (es)
KR (1) KR20160093047A (es)
CN (2) CN110354258A (es)
BR (1) BR112016012435A8 (es)
CA (1) CA2931137C (es)
DK (1) DK3076996T3 (es)
ES (1) ES2771899T3 (es)
MX (1) MX369039B (es)
PL (1) PL3076996T3 (es)
RU (1) RU2712155C2 (es)
WO (1) WO2015082458A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10130698B2 (en) 2013-12-03 2018-11-20 Intervet Inc. Vaccine against porcine circo virus type 2
BR112018007918A2 (pt) * 2015-10-22 2018-10-30 Intervet Int Bv vacina, uso de antígeno de lawsonia intracellularis inativada, e, método para proteger um animal.
BR112018069219A2 (pt) * 2016-03-23 2019-01-22 Intervet Int Bv uma vacina para aplicação intradérmica contra infecção pelo vírus pcv2 e prrs
CN110446502B (zh) * 2017-04-13 2024-01-26 英特维特国际股份有限公司 用于联合非混合使用的含猪病原体的疫苗

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502054A (ja) 1995-11-30 2000-02-22 アグリカルチャー ビクトリア サービシーズ ピーティーワイ．エルティーディー． 治療用および診断用の組成物
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
US7276353B2 (en) 2001-12-12 2007-10-02 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
CA2533581C (en) * 2003-07-24 2012-05-08 Merial Limited Vaccine formulations comprising an oil-in-water emulsion
WO2005070958A2 (en) 2004-01-22 2005-08-04 Intervet International B.V Lawsonia intracellularis subunit vaccines
US7833707B2 (en) * 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
UA95458C2 (ru) * 2005-09-09 2011-08-10 Интервет Интернешонал Б.В. Вакцина против pcv-2 у mda-положительных поросят
WO2007094893A2 (en) 2005-12-29 2007-08-23 Boehringer Ingelheim Vetmedica, Inc. Use of a pcv2 immunogenic composition for lessening clinical symptoms in pigs
US20100129397A1 (en) 2006-12-11 2010-05-27 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
PL2094872T5 (pl) * 2006-12-15 2020-10-05 Boehringer Ingelheim Animal Health USA Inc. Leczenie świń seropozytywnych wobec przeciwciała anty-pcv2 antygenem pcv2
EP1958644A1 (en) * 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
CA2712006A1 (en) * 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
TWI449533B (zh) * 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
UA114503C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
UA114504C2 (uk) * 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
EP3673916A1 (en) 2013-12-03 2020-07-01 Intervet International B.V. Vaccine against lawsonia intracellularis and porcine circovirus2
US10130698B2 (en) 2013-12-03 2018-11-20 Intervet Inc. Vaccine against porcine circo virus type 2

Also Published As

Publication number Publication date
US20170157236A1 (en) 2017-06-08
BR112016012435A8 (pt) 2018-01-30
JP2017501984A (ja) 2017-01-19
CN105848675A (zh) 2016-08-10
KR20160093047A (ko) 2016-08-05
CN110354258A (zh) 2019-10-22
WO2015082458A1 (en) 2015-06-11
DK3076996T3 (en) 2020-03-09
EP3076996B1 (en) 2020-01-15
MX2016007224A (es) 2016-07-21
EP3076996A1 (en) 2016-10-12
JP6605469B2 (ja) 2019-11-13
RU2712155C2 (ru) 2020-01-24
US10130698B2 (en) 2018-11-20
BR112016012435A2 (pt) 2017-08-08
CA2931137C (en) 2023-03-14
CA2931137A1 (en) 2015-06-11
PL3076996T3 (pl) 2020-05-18
ES2771899T3 (es) 2020-07-07

Similar Documents

Publication Publication Date Title
PH12018500573A1 (en) Hepatitis b core protein modulators
MX2019003525A (es) Moduladores alostericos de proteina nucleo de hepatitis b.
MX2021015329A (es) Composiciones a base de nanoparticulas.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
BR112015022197A2 (pt) tratamento de cataplexia
EA201591987A1 (ru) Лечение злокачественной опухоли дигидропиразинопиразинами
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
PH12016502002A1 (en) Novel bacteriophage and composition comprising same
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
PH12019501722A1 (en) Compositions and methods for promoting hair growth with mpc1 inhibitors
MX2017006709A (es) Agente para prevenir o mejorar sintomas causados por desequilibrio de las hormonas sexuales.
WO2016011324A3 (en) 5'-triphosphate oligoribonucleotides
EA201691860A1 (ru) Пептидный медикамент в виде сухого порошка
PH12016500946A1 (en) Composition for preventing and curing mycoplasma infection
MX2016007224A (es) Vacuna contra el circovirus porcino tipo 2.
WO2015051371A3 (en) Haemophilus parasuis vaccine serovar type four
EA201591434A1 (ru) Способ обеспечения глазной нейропротекции
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
MX2019003258A (es) Composiciones inmunogénicas de consenso sintéticas optimizadas que seleccionan la proteína de activación de fibroblastos como diana.
MX2018000379A (es) Material no tejido tratado que tiene una afinidad por un ingrediente activo.
EA201790991A1 (ru) Способ лечения с использованием пегилированного интерферона
MX2020006061A (es) Una vacuna para proteccion contra streptococcus suis.
EA201790220A1 (ru) Лечение симптомов, связанных с андроген-депривационной терапией
AR099416A1 (es) Terapia combinada para la hipertensión resistente

Legal Events

Date Code Title Description
FG Grant or registration